• Activartis Biotech GmbH, of Vienna, Austria, said it expects interim results from an ongoing Austrian Phase II trial of its cancer vaccine in glioblastoma multiforme in the second half of next year. Activartis' technology uses autologous dendritic cells to activate tumor-specific T cells and activates release of interleukin 12, a signaling molecule key to polarizing an immune response based on killer T-cell activity. The primary objective of the randomized, open-label, two-arm trial is progression-free survival, with overall survival as the secondary goal.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter